Targets › LY6G6D
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Apr 2029.
Open in Phaseline: the race on LY6G6D, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Cartography Biosciences | CBI-1214 Bispecific T cell engager targeting LY6G6D on colorectal cancer cells and CD3 on T cells | LY6G6D, CD3 | Phase 1 | Colorectal Cancer | Apr 2029 |
Colorectal Cancer (1)
protein or peptide (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.